Perrigo Company PLC

PRGO

14.640USD

+0.370+2.59%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Perrigo Company PLC's Score

Industry at a Glance

Industry Ranking

71 / 159

Overall Ranking

186 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Perrigo Company PLC Highlights

StrengthsRisks

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.37B.

Fairly Valued

The company’s latest PE is -38.96, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 146.26M shares, decreasing 15.02% quarter-over-quarter.

Held by Keeley-Teton Advisors, LLC

Star Investor Keeley-Teton Advisors, LLC holds 375.68K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.25.

Analyst Rating

Based on 4 analysts

Hold

Current Rating

18.667

Target Price

+30.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Perrigo Company PLC is 6.99, ranking 134 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 1.04B, representing a year-over-year decrease of 4.06%, while its net profit experienced a year-over-year decrease of 135.71%.

Score

Industry at a Glance

Previous score

6.99

Change

0



Financials

6.64

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.75

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.64

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.34

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Perrigo Company PLC is 7.19, ranking 93 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -38.96, which is -52.32% below the recent high of -18.57 and -2600.22% above the recent low of -1051.98.

Score

Industry at a Glance

Previous score

7.19

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Perrigo Company PLC is 6.50, ranking 127 out of 159 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 20.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

6.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Perrigo Company PLC is 7.14, ranking 77 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 15.48 and the support level at 13.69, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.84

Change

0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Perrigo Company PLC is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 106.27%, representing a quarter-over-quarter decrease of 1.22%. The largest institutional shareholder is PRFDX, holding a total of 16.79M shares, representing 12.20% of shares outstanding, with 52.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Associates, Inc.

Star Investors

16.79M

+16.34%

The Vanguard Group, Inc.

Star Investors

13.82M

-1.04%

BlackRock Institutional Trust Company, N.A.

11.97M

+1.78%

Dimensional Fund Advisors, L.P.

7.70M

+2.42%

State Street Investment Management (US)

6.90M

-5.96%

Neuberger Berman, LLC

5.73M

+54.36%

Cooke & Bieler, L.P.

3.68M

+11.56%

Sound Shore Management, Inc.

3.65M

+11.05%

Thompson, Siegel & Walmsley LLC

3.63M

+56.12%

Millennium Management LLC

3.17M

+279.90%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Perrigo Company PLC is 5.06, ranking 78 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.40. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Perrigo Company PLC

PRGO

7.06 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment